First Trust Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
– Sell
-8,986
Closed -$958K – 2313
2020
Q3
$958K Buy
+8,986
New +$1.25M ﹤0.01% 1777
2020
Q2
– Sell
-1,405
Closed -$117K – 2363
2020
Q1
$117K Buy
+1,405
New +$198K ﹤0.01% 2285
2019
Q4
– Sell
-13,109
Closed -$2.43M – 2385
2019
Q3
$2.43M Buy
13,109
+1,876
+17% +$363K ﹤0.01% 1427
2019
Q2
$2.57M Buy
+11,233
New +$2.2M ﹤0.01% 1422
2019
Q1
– Sell
-4,152
Closed -$477K – 2409
2018
Q4
$477K Buy
+4,152
New +$615K ﹤0.01% 2143
2018
Q3
– Sell
-3,361
Closed -$750K – 2433
2018
Q2
$750K Sell
3,361
-3,192
-49% -$714K ﹤0.01% 2032
2018
Q1
$1.5M Buy
+6,553
New +$1.72M ﹤0.01% 1625
2017
Q4
– Sell
-8,880
Closed -$1.99M – 2384
2017
Q3
$1.99M Buy
8,880
+4,458
+101% +$1.09M 0.01% 1473
2017
Q2
$1.21M Buy
+4,422
New +$1.2M ﹤0.01% 1766
2017
Q1
– Sell
-8,011
Closed -$1.66M – 2382
2016
Q4
$1.66M Buy
+8,011
New +$1.9M ﹤0.01% 1561

Other funds holding AXDX

First Trust Advisors's AXDX Position: Q4 2020 in Review

First Trust Advisors sold out of Accelerate Diagnostics (AXDX) in Q4 2020, closing a stake of 8,986 shares — an estimated $958K sold.

First Trust Advisors first reported a position in AXDX in Q4 2016 and held it in 10 quarters. The position peaked at $2.57M in Q2 2019. 115 funds tracked by Wall St. Rank hold AXDX as of Q4 2020.

  • First Trust Advisors reported no remaining Accelerate Diagnostics position as of Q4 2020 after selling out during the quarter.
  • First Trust Advisors sold 8,986 Accelerate Diagnostics shares in Q4 2020, an estimated $958K.
  • First Trust Advisors first reported a position in Accelerate Diagnostics in Q4 2016 and held it in 10 quarters.
  • First Trust Advisors's Accelerate Diagnostics position peaked at $2.57M in Q2 2019.
  • 115 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2020.

Based on First Trust Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.